Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (101-110 of 139) with videos related to

Pageof 14
Sort By:
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerMaria Coakley, Guillermo Villacampa, Prithika Sritharan, et al.
JAMA Oncology|August 2, 2019
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac Garcia-Murillas, Neha Chopra, Iñaki Comino-Méndez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyRina Hui, Alex Pearson, Javier Cortes, et al.
Future Oncology (London, England)|September 16, 2024
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Pageof 14

Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerMaria Coakley, Guillermo Villacampa, Prithika Sritharan, et al.
JAMA Oncology|August 2, 2019
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac Garcia-Murillas, Neha Chopra, Iñaki Comino-Méndez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyRina Hui, Alex Pearson, Javier Cortes, et al.
Future Oncology (London, England)|September 16, 2024
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Pageof 14